Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A potent protein kinase A (PKA)-selective kinase inhibitor, BLU0588, stabilizes the PKA catalytic subunit in an unusual open conformation”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [24]
In the citing paper
“Down-regulation of PKA-C activity slows the progression of polycystic kidney disease (3, 24, 25)”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [24]
In the citing paper
“This pharmacokinetically favorable drug successfully targeted tumor cells and PKA-C activity in murine xenograft models and showed the power of selectively targeting PKA in a cellular environment (24).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [24]
In the citing paper
“To explore the etiology of FL-HCC more deeply, Blueprint Medicines developed a small-molecule ATP-competitive PKA-selective inhibitor, BLU0588 (24, 31).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [24]
In the citing paper
“The resulting apparent inhibitory constant (Ki) of BLU0588 was determined to be 230 ± 10 pM (Fig. 5E) supporting the data by Schalm et al. (24).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [24]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome
Beuschlein, F., Fassnacht, M., Assié, G., Calebiro, D., Stratakis, C. A., Osswald, A., Ronchi, C. L., Wieland, T., Sbiera, S., Faucz, F. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310359 · Cited by 443
Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome
Cao, Y., He, M., Gao, Z., Peng, Y., Li, Y., Li, L., Zhou, W., Li, X., Zhong, X., Lei, Y., et al. (2014) · Science · doi:10.1126/science.1249480 · Cited by 232
Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome
Sato, Y., Maekawa, S., Ishii, R., Sanada, M., Morikawa, T., Shiraishi, Y., Yoshida, K., Nagata, Y., Sato-Otsubo, A., Yoshizato, T., et al. (2014) · Science · doi:10.1126/science.1252328 · Cited by 209
Role of cAMP and phosphodiesterase signaling in liver health and disease
Wahlang, B., McClain, C., Barve, S., & Gobejishvili, L. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.06.005 · Cited by 168
Di Dalmazi, G., Kisker, C., Calebiro, D., Mannelli, M., Canu, L., Arnaldi, G., Quinkler, M., Rayes, N., Tabarin, A., Laure Jullié, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2152 · Cited by 119
Olivieri, C., Walker, C., Karamafrooz, A., Wang, Y., Manu, V. S., Porcelli, F., Blumenthal, D. K., Thomas, D. D., Bernlohr, D. A., Simon, S. M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01819-6 · Cited by 27
Research works printed but not linked: 43
- Riggle, 2016, Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma, Pediatr Blood Cancer, 63, 1163, 10.1002/pbc.25970 · DOI · Paper page
- Eggert, 2013, Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database, United European Gastroenterol J, 1, 351, 10.1177/2050640613501507 · doi:10.1177/2050640613501507
- Ang, 2013, Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium, Gastrointest Cancer Res, 6, 3
- Kaseb, 2013, Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma, Oncology, 85, 197, 10.1159/000354698 · doi:10.1159/000354698
- Groeschl, 2014, Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma, J Surg Oncol, 110, 412, 10.1002/jso.23658 · doi:10.1002/jso.23658
- Stipa, 2006, Outcome of patients with fibrolamellar hepatocellular carcinoma, Cancer, 106, 1331, 10.1002/cncr.21703 · doi:10.1002/cncr.21703
- Chakrabarti, 2019, Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma, J Gastrointest Oncol, 10, 554, 10.21037/jgo.2019.01.35 · doi:10.21037/jgo.2019.01.35
- Ward, 2011, Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors, Semin Liver Dis, 31, 61, 10.1055/s-0031-1272835 · doi:10.1055/s-0031-1272835
- Ward, 2010, Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation, Mod Pathol, 23, 1180, 10.1038/modpathol.2010.105 · DOI
- Ross, 2011, Fibrolamellar carcinomas are positive for CD68, Mod Pathol, 24, 390, 10.1038/modpathol.2010.207 · doi:10.1038/modpathol.2010.207
- Capurro, 2003, Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016/S0016-5085(03)00689-9 · DOI · Paper page
- Dinh, 2017, Comprehensive analysis of the Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma, Sci Rep, 7, 44653, 10.1038/srep44653 · DOI
- Simon, 2015, Transcriptomic characterization of fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci U S A, 112, E5916, 10.1073/pnas.1424894112 · DOI · Paper page
- Honeyman, 2014, Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma, Science, 343, 1010, 10.1126/science.1249484 · DOI · Paper page
- Cornella, 2015, Unique genomic profile of fibrolamellar hepatocellular carcinoma, Gastroenterology, 148, 806, 10.1053/j.gastro.2014.12.028 · DOI
- Engelholm, 2017, CRISPR/Cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma, Gastroenterology, 153, 1662, 10.1053/j.gastro.2017.09.008 · DOI
- Kastenhuber, 2017, DNAJB1-PRKACA fusion kinase interacts with beta-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma, Proc Natl Acad Sci U S A, 114, 13076, 10.1073/pnas.1716483114 · DOI · Paper page
- Turnham, 2019, An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma, Elife, 8, e44187, 10.7554/eLife.44187 · DOI · Paper page
- Dinh, 2019, MicroRNA-375 suppresses the growth and invasion of fibrolamellar carcinoma, Cell Mol Gastroenterol Hepatol, 7, 803, 10.1016/j.jcmgh.2019.01.008 · DOI
- Graham, 2015, DNAJB1-PRKACA is specific for fibrolamellar carcinoma, Mod Pathol, 28, 822, 10.1038/modpathol.2015.4 · DOI · Paper page
- Turnham, 2016, Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology, Gene, 577, 101, 10.1016/j.gene.2015.11.052 · DOI · Paper page
- Riggle, 2016, Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma, Pediatr Res, 80, 110, 10.1038/pr.2016.36 · DOI · Paper page
- Cheung, 2015, Structural insights into mis-regulation of protein kinase A in human tumors, Proc Natl Acad Sci U S A, 112, 1374, 10.1073/pnas.1424206112 · DOI · Paper page
- Thatte, 2017, Kinase inhibitor demonstrates efficacy in a patient-derived xenograft model of fibrolamellar hepatocellular carcinoma featuring DNAJB1-PRKACA fusion, Cancer Res, 77, 4203, 10.1158/1538-7445.AM2017-4203 · doi:10.1158/1538-7445.am2017-4203
- Leinonen, 2017, Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours, Eur J Cancer, 77, 31, 10.1016/j.ejca.2017.02.017 · DOI · Paper page
- Davis, 2011, Comprehensive analysis of kinase inhibitor selectivity, Nat Biotechnol, 29, 1046, 10.1038/nbt.1990 · DOI · Paper page
- Oikawa, 2015, Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells, Nat Commun, 6, 8070, 10.1038/ncomms9070 · DOI
- Patro, 2017, Salmon provides fast and bias-aware quantification of transcript expression, Nat Methods, 14, 417, 10.1038/nmeth.4197 · DOI · Paper page
- Liberzon, 2015, The Molecular Signatures Database (MSigDB) hallmark gene set collection, Cell Syst, 1, 417, 10.1016/j.cels.2015.12.004 · DOI · Paper page
- Isobe, 2017, Systems-level identification of PKA-dependent signaling in epithelial cells, Proc Natl Acad Sci U S A, 114, E8875, 10.1073/pnas.1709123114 · DOI
- Dinh, 2020, Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal candidate oncogenic pathways and therapeutic vulnerabilities, Cell Rep, 31, 107509, 10.1016/j.celrep.2020.03.073 · DOI
- Spath, 1997, Hepatocyte nuclear factor 4 expression overcomes repression of the hepatic phenotype in dedifferentiated hepatoma cells, Mol Cell Biol, 17, 1913, 10.1128/MCB.17.4.1913 · DOI · Paper page
- Viollet, 1997, Protein kinase A-dependent phosphorylation modulates DNA-binding activity of hepatocyte nuclear factor 4, Mol Cell Biol, 17, 4208, 10.1128/MCB.17.8.4208 · DOI · Paper page
- Liu, 2009, cAMP enhances estrogen-related receptor alpha (ERRalpha) transcriptional activity at the SP-A promoter by increasing its interaction with protein kinase A and steroid receptor coactivator 2 (SRC-2), Mol Endocrinol, 23, 772, 10.1210/me.2008-0282 · DOI
- Xia, 2019, ERRalpha as a bridge between transcription and function: role in liver metabolism and disease, Front Endocrinol (Lausanne), 10, 206, 10.3389/fendo.2019.00206 · DOI
- Cao, 2019, Structures of the PKA RIalpha holoenzyme with the FLHCC driver J-PKAcalpha or wild-type PKAcalpha, Structure, 27, 816, 10.1016/j.str.2019.03.001 · DOI · Paper page
- Lalazar, 2021, Identification of novel therapeutic targets for fibrolamellar carcinoma using patient derived xenografts and direct from patient screening, Cancer Discov, 11, 2544, 10.1158/2159-8290.CD-20-0872 · DOI
- Goh, 2014, Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors, Nat Genet, 46, 613, 10.1038/ng.2956 · DOI · Paper page
- Nakajima, 2014, Somatic mutations of the catalytic subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients with several adrenal adenomas secreting cortisol [Rapid Communication], Endocr J, 61, 825, 10.1507/endocrj.EJ14-0282 · DOI · Paper page
- Forlino, 2014, PRKACB and Carney complex, N Engl J Med, 370, 1065, 10.1056/NEJMc1309730 · DOI
- Yin, 2011, Differential role of PKA catalytic subunits in mediating phenotypes caused by knockout of the Carney complex gene Prkar1a, Mol Endocrinol, 25, 1786, 10.1210/me.2011-1008 · DOI
- Moody, 2015, PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling, Oncogene, 34, 2061, 10.1038/onc.2014.153 · DOI · Paper page
- Vyas, 2020, DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma, Mod Pathol, 33, 648, 10.1038/s41379-019-0398-2 · DOI · Paper page
Cited by
Gritti, I., Wan, J., Weeresekara, V., Vaz, J. M., Tarantino, G., Bryde, T. H., Vijay, V., Kammula, A. V., Kattel, P., Zhu, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0634 · Cited by 20
Bruystens, J. G. H., Wu, J., Tan, G., Bertinetti, D., Zenn, H.-M., Zimmermann, B., Chen, L., Köckenberger, J., Massaro, F., Sankaran, B., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536312123 · Cited by 3
Metadata
- Authors
- Schalm, S. S., O’Hearn, E., Wilson, K., LaBranche, T. P., Silva, G., Zhang, Z., DiPietro, L., Bifulco, N., Woessner, R., Stransky, N., Sappal, D., Campbell, R., Lobbardi, R., Palmer, M., Kim, J., Ye, C., Dorsch, M., Lengauer, C., Guzi, T., Kadambi, V., Garner, A., & Hoeflich, K. P.
- Venue
- Gastro Hep Advances
- Publisher
- Elsevier BV
- Published
- 2023
- Volume
- 2
- Issue
- 3
- Pages
- 307-321
- ISSN
- 2772-5723
- Cited by
- 14
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. https://app.cochat.ai/papers/10.1016/j.gastha.2022.11.004
- The paper
- Schalm, S. S., O’Hearn, E., Wilson, K., LaBranche, T. P., Silva, G., Zhang, Z., DiPietro, L., Bifulco, N., Woessner, R., Stransky, N., Sappal, D., Campbell, R., Lobbardi, R., Palmer, M., Kim, J., Ye, C., Dorsch, M., Lengauer, C., Guzi, T., . . . Hoeflich, K. P. (2023). Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. Gastro Hep Advances. https://doi.org/10.1016/j.gastha.2022.11.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.